Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem. Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.
Unlock the market timeline & signal feed
New Footprint activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Sisram Medical Advances Global Wellness Strategy
BPD Conference Expands Global Biopharmaceutical Network
Sign up to see the full signal feed
How Fosun Pharma's international expansion compares to its competitors
Fosun PharmaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Fosun PharmaYou | 4 | 1 | -50% | 6 | 30 |
Sales Manager (Cebu and Davao based) - Pharmaceutical/IVD/Medical Device
View postingTaguig, National Capital Region, Philippines · 6d ago
Medical Representative (Cardiology/Medical Device) - NCR based
View postingTaguig, National Capital Region, Philippines · 4w ago
Sales Manager (Pharma/IVD/Medical Device) - NCR based
View postingTaguig, National Capital Region, Philippines · last mo.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Fosun Pharma reported strong H1 2025 results with revenue of RMB 19,514 million and net profit of RMB 1,702 million, driven by innovation and global expansion.
Fosun International's H1 2025 revenue reached RMB87.28 billion, with core subsidiaries contributing 73%. Innovation and globalization drove growth across pharmaceuticals, tourism, and insurance sectors.
Futoning®, a CDK4/6 inhibitor, has been launched in China for treating HR-positive, HER2-negative metastatic breast cancer patients who progressed after endocrine therapy.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Fosun Pharma's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
